Physician

Jay T Guevarra, M.D.

According to 2025 Medicare claims, Jay Guevarra, M.D. (NPI: 1215291620) practices sleep medicine in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (NPI: 1518228550; TIN: 611661781) and primary practice location at 10023-7903. Guevarra is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Guevarra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 233 traditional Medicare patients, billed 450 HCPCS/CPT codes, and received $43,080 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 707 prescription claims across 138 beneficiaries totaling $157,160 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 1,092 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $11,122 to $43,080. Similarly, Part D prescription costs have risen steadily, from $2,153 to $157,160. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	52	147	$11,122
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	56	140	$13,630
2021	220	368	$40,318
2022	198	313	$31,470
2023	228	396	$42,682
2024	233	450	$43,080

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	12	45	$2,153
2016	16	58	$8,416
2017	25	83	$14,384
2018	34	167	$62,760
2019	30	154	$65,757
2020	N/R	21	$956
2021	41	193	$38,664
2022	65	232	$44,373
2023	122	552	$135,918
2024	138	707	$157,160

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	107	175	$5,579
2022	293	587	$20,979
2023	397	957	$36,337
2024	435	1,092	$45,703

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	62	62	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	79	115	$106
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	31	87	$102
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	33	38	$79
G0399	Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation	30	30	$40

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	47	1,410	$30,440
Spiriva Respimat	Tiotropium Bromide	33	1,530	$26,507
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	47	1,650	$24,923
Breo Ellipta	Fluticasone/Vilanterol	49	1,650	$20,591
Incruse Ellipta	Umeclidinium Bromide	25	870	$9,744

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A7032	Cushion for use on nasal mask interface, replacement only, each	N	25	66	$6,242
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	N	45	120	$5,927
A7030	Full face mask used with positive airway pressure device, each	N	25	66	$5,402
A7031	Face mask interface, replacement for full face mask, each	N	25	62	$5,206
A4604	Tubing with integrated heating element for use with positive airway pressure device	N	52	134	$4,837

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Jay T. Guevarra, M.D.?

Tedicare shows public-source Medicare data for Jay T. Guevarra, M.D. (NPI 1215291620), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jay T. Guevarra, M.D. have ACO affiliation data?

Jay T. Guevarra, M.D. is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Jay T. Guevarra, M.D.?

Jay T. Guevarra, M.D. is linked to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (billing NPI 1518228550) in the available physician profile data.

Does Jay T. Guevarra, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.